PeproMene Bio, Inc. announced a patient in their Phase 1 trial for PMB-CT01 (BAFFR-CAR T Cells) achieved complete remission post-treatment for relapsed/refractory B-cell acute lymphoblastic leukemia. The trial, conducted at City of Hope, showed minimal toxicity and durable remissions, highlighting PMB-CT01's potential in treating B-cell malignancies.